Refractory myasthenia gravis (MG): clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Refractory myasthenia gravis (MG): clinical features. This is inadequate response to conventional MG treatment for ≥12 months.
Definition
- This is inadequate response to conventional MG treatment for ≥12 months
- It also describes disease relapse when immunosuppressive drug doses are reduced
- It develops in 10% of people with MG
Risk factors
Locked: subscribe to see this section.
Risk medical factors
Locked: subscribe to see this section.
Course
Locked: subscribe to see this section.
References
- Sudulagunta SR, Sepehrar M, Sodalagunta MB, et al. Refractory myasthenia gravis-clinical profile, comorbidities and response to rituximab. Ger Med Sci 2016; 14:Doc12.
- Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013; 86:255-260.
- Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 2018; 11:1756285617749134.
- Sudulagunta SR, Sepehrar M, Sodalagunta MB, et al. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. Ger Med Sci 2016; 14:Doc12.
